Merck KGaA (MRK) Earnings Call Transcripts
Merck KGaA's Latest Earnings Call - Q3 FY2026
In the third quarter of 2026, Merck & Co., Inc. reported revenues of $18.1 billion, reflecting a 5% increase year-over-year, driven by strong contributions from new products and oncology. The company achieved earnings per share (EPS) of $2.49, which includes a $0.12 charge related to a license agreement. Management raised the midpoint of their full-year revenue and EPS guidance, now expecting revenue between $66.8 billion and $67.3 billion and EPS of $2.77 to $2.82, signaling confidence in their expanding pipeline and product launches.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $18.1 billion |
| EPS | $2.49 |
| GARDASIL Sales | $2 billion |
| WINREVAIR Sales | $694 million |
| Operating Expenses | $7.4 billion |
| Gross Margin | 81.4% |
Guidance from management
Merck has raised the midpoint of its full-year revenue guidance to between $66.8 billion and $67.3 billion, expecting growth of 3% to 4%. EPS guidance is now projected to be between $2.77 and $2.82.
What management said
Thanks, Dean. Before we begin the Q&A, I’m really glad to welcome Jannie Oosthuizen and Brian Foard, who are joining us this morning to help take questions; and just to remind everyone, Jannie is President of our Oncology business unit and also of MSD International, while Brian is President of our Specialty Pharma and Infectious Diseases business unit. I’d also ask that analysts please stick to one question each toda...
Thanks, Vamil, for that question. About the timing benefits we saw this quarter, let me lay out the complete picture, WINREVAIR included, so everyone has it: in the third quarter we saw a benefit of $550 million stemming from the timing of purchases. Of that amount, $200 million is tied to KEYTRUDA, and we expect it to fully unwind in the fourth quarter. $50 million is tied to WINREVAIR, which we also expect to unwin...
What analysts pressed on
Analysts expressed concerns regarding the potential headwinds from generic competition impacting key products like BRIDION and JANUVIA in 2027. There is also apprehension about the sustainability of growth as the company approaches the KEYTRUDA LOE period.
Main topics on the call
- Revenue Growth — Merck reported third-quarter revenues of $18.1 billion, a 5% increase year-over-year, with oncology sales contributing significantly. CEO Rob Davis stated, "We're executing well on all fronts, demonstrated particularly b...
- KEYTRUDA Performance — Sales of the KEYTRUDA family increased 6% to $8.6 billion, driven by strong demand in earlier-stage cancers. Caroline Litchfield noted, "We continue to see adoption increase, which supports our confidence in the trajecto...
- Guidance Update — Management raised the midpoint of their full-year guidance, now expecting revenue between $66.8 billion and $67.3 billion. Caroline Litchfield stated, "We have narrowed the range and raised the midpoint of both our full ...
- Clinical Milestones — Merck achieved several important clinical milestones, particularly in oncology, with positive Phase III results for sac-TMT in endometrial cancer. Dean Li highlighted, "We look forward to continuing to work with the FDA ...
Read the full Merck KGaA transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Merck KGaA
Merck KGaA (MRK) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on Deutsche Boerse Xetra and is based in DE. EarningsCalls.dev maintains a full-text archive of its earnings call transcripts — 58 calls on record spanning February 5, 2020 to November 12, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics. The latest calls are free to read; the full history is available through our REST API.
Earnings Call History
EarningsCalls.dev has 58 Merck KGaA earnings call transcripts on record, spanning February 5, 2020 to November 12, 2026. Based on this history, Merck KGaA reports quarterly. The most recent call on file is dated November 12, 2026. The full list is below — each row opens the transcript.
- Ticker
- MRK
- Exchange
- Deutsche Boerse Xetra
- Country
- DE
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 58
- First call
- February 5, 2020
- Most recent
- November 12, 2026
- Reporting cadence
- quarterly